Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (May 2022)
27 slides from Matinas Biopharma's investor presentation, May 12, 2022
Slide 1: Corporate Presentation May 2022
MATINA BIOPHARMA X Corporate present May 2022
Slide 2: Forward-Looking Statements
Forward-Looking Stateme This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other statem
Slide 3: Lipid Nanocrystals (LNCs) Simplify Intracellular Delivery of Nucleic Acids
Lipid Nanocrystals (LNCs) Simplify Intracellular Delivery of Nucleic Acids Description Benefit % JNINETEEY TARGET aereP lages/monocytesneatroptils = Wide variety of extrahepatic ee) ‘ACTIVATED” CELLS dendritic cells Sareet = Infected/injured cells, tumor cells angers = Non-immunogenic platform IMPRO
Slide 4: Matinas Pipeline and Discovery Programs: Internal Clinical Stage Assets and External Collaborations
Matinas Pipeline and Discovery Programs: Internal Clinical Stage Assets and External Collaborations MATINAS a& MATINAS cystic FIBROS! FOUNDATION’ ciLeaD [{) Genentech A Member of the Roche Group BIONT=CH MATINAS 310 PHARMA 4 LYPDISO™ Program Indication Discovery Preclinical Phase 1 Phase 2 MAT2203 L
Slide 5: Exclusive Research Collaboration with BioNTech
Exclusive Research Collaboration with BioNTech MATINAS o3lO —Cr BIOPHARMA Exclusive collaboration between Matinas and BioNTech focused on mRNA and certain other nucleic acids BioNTech’s mRNA vaccine development expertise combined with Matinas’ LNC delivery platform Builds on Matinas’ extensive prior
Slide 6: Exclusive Research Collaboration with BioNTech Builds on Previous Vaccine Results
Exclusive Research Collaboration with BioNTech Builds on Previous Vaccine Results EfriCaey previously demonstrated LNCs Provide Differentiation w/LNCs (in-vivo) Y Successful oral immunization Y Can be administered SQ, IM, via Y Substantial increases in antibody titers inhalation, and orally * Out to
Slide 7: Lipid Nanocrystal (LNC) Platform
Lipid Nanocrystal (LNC) Platform Targeted, Well-Tolerated Intracellular Delivery ‘e) MATINAS BIOPHARMA
Slide 8: LNCs Provide A Strong Alternative to LNP and AAV Delivery
LNCs Provide A St g Alternative to LNP and AAV Delivery * lonizable lipid complexing with mRNA Natural components Structure * Non-aqueous interior 26.niMicapsidihousing: * Non-aqueous bilayer ; . , re + Limited set of targeted tissues + Targeted to phagocytes and activated cells (e.g. + Avid upt: R
Slide 9: Lipid Nanocrystals Consist of Phosphatidylserine, Calcium and Cargo and Deliver Cargo Intracellularly
Lipid Nanocrystals (LNCs) Consist of Phosphatidylserine, Calcium and Cargo and Deliver Cargo Intracellularly ¢ Stable, phospholipid-calcium crystalline nanoparticles * Calcium (Ca**) — Phosphatidylserine (PS) crystalline shell ° Engineered to self-assemble into nano-crystals in the Phosphatidy-_| pr
Slide 10: LNCs Work Because of PS, Which Enables Intracellular Delivery Via Two Biological Pathways
10 Cs Work Because of PS, Which Enables Intracellular Delivery Via Two Biological Pathways Phosphatidylserine. PS on the outer layer is an “eat-me” signal enabling phagocytosis Infection Injury Inflammation Cell membrane Cell membrane Cytosol With “activation” Normally, PS is PS moves from the confi
Slide 11: LNCs Have the Potential to Target a Wide Array of Cells & Tissues
LNCs Have the Potential to Target a Wide Array of Cells & Tissues Cells with PS Receptors or Expressing High PS Levels Demonstrated uptake Bone marrow-derived hematopoietic cells = Macrophages v = Dendritic cells Cells Capable = Natural killer (NK) cells of Astrocytes and microglial cells (CNS macro
Slide 12: Multiple Potential Future Directions For LNC Platform
Multiple Potential Future Directions For LNC Platform Past Current Future , Antivirals Infection Intracellular delivery of oo Immune system nucleic acids Immune tolerance Oral Inflammation formulations of anti- onesla infectives By Diseases of F . Monogenetic rare diseases phagocytes ; . Organ fibro
Slide 13: In vivo Assessment of the Efficacy of LNC-remdesivir in SARS-CoV-2 Infection
In vivo Assessment of the Efficacy of LNC-remdesivir in SARS-CoV-2 Infection Evaluate the capacity of an orally bioavailable remdesivir formulation to block Goal: viral replication and prevent severe disease in a mouse model of SARS-CoV-2* * Leist and Dinnon et al., Cell 2020. ° 10-week-old female B
Slide 14: In vivo Assessment of the Efficacy of LNC-remdesivir in SARS-CoV-2 Infection
In vivo Assessment of the Efficacy of LNC-remdesivir in SARS-CoV-2 Infection 2 ° oS : 110 ° — > 2 3 $ 100 7) 2 D o | < a ie g 90 S > ° 2 4 80 ry £ e 70 1 r tr . r 1 Day5 Day2 Day5 Day5 Day2 Day5 4 SQ a ° 7 2 7 . a . Uninfected | | Remdesivir | a Days Post Infection Day 2 Day 5 Infected Oral y y Untr
Slide 15: MAT2203 Oral Amphotericin B
MAT2203 Oral Amphotericin B MATINAS
Slide 16: MAT2203: A Novel Approach with a Proven Therapeutic Agent
MAT2203: A Novel Approach with a Proven Therapeutic Agent = Oral amphotericin B formulation utilizing LNCs = Proprietary formulation with robust intellectual property protection MAT2203 ads adie = Potential to expand beyond treatment of CM to treatment of other invasive infections and prophylaxis =
Slide 17: Study Design
Study Design Induction (2 weeks) v Cohort 1 [RAN (n=10) 5 days v¥ Cohort2 [WWE Early Consolidation (4 weeks) (n=40) 2 days v Cohort 3 IV AMB (n=10) days (overlap 1 day) 1 i Cohort 4 ! (n=40) 1 J 1 I Adjunctive Rx SFC ! (all cohorts) ” *|V AMB = intravenous amphotericin B Fluconazole |» MAT2203 TREAT
Slide 18: EnACT Cohort Met Primary Endpoints — Effective at Delivering Drug ACROSS Blood Brain Barrier
EnACT Cohort 2 Met Primary Endpoints — Effective at Delivering Drug ACROSS Blood Brain Barrier EnACT Cohort 2 Endpoints EnACT Cohort 2 Results = Primary Endpoint: Early Fungicidal Activity (EFA) log,,. CFU/mL/day at Day 14 >0.2 = EFA > 0.20 - associated with lower mortality and improved clinical v E
Slide 19: MAT2203 EnACT Cohort Update
19 MAT2203 En EnACT Cohort 4 Update All-oral regimen administered during induction (14 days) followed by consolidation treatment through Week 6 Target: 40 patients on MAT2203 and 16 patients on SoC 50% enrolled (28 patients) through May 12% First DSMB review already conducted with recommendation to
Slide 20: MAT2203 Regulatory Updates: Pathway to NDA Approval and Phase 3 Registration Trial
MAT2203 Regulatory Updates: Pathway to NDA Approval and Phase 3 Registration Trial Follow-up Clinical Type C Meeting held April 2022 > FDA is evaluating potential registration of MAT2203 for both step-down induction and consolidation indications based upon the conduct of a single Phase 3 Trial ¢ Rep
Slide 21: MAT2501 Oral Amikacin
MAT2501 Oral Amikacin MATINAS
Slide 22: MAT2501: A Better Amikacin
2: MAT2501: A Better Amikacin MAT2501 IMPROVED PROFILE SIGNIFICANT UNMET NEED Oral, LNC formulation of the broad-spectrum antibiotic Amikacin Initial indication in treatment of non-tuberculous mycobacterial (NTM) infections QIDP and Orphan Designations potentially provide 12+ years of exclusivity up
Slide 23: NTM Program Overview and SAD Topline Results
1: NTM Program Overview and SAD Topline Results Non-Tuberculous Mycobacterial Disease NTM organisms, widely present in the environment, are a frequent cause of challenging pulmonary S infections, especially in patients with pre-existing inflammatory lung diseases such as cystic fibrosis Approximatel
Slide 24: Expanding LNC Intellectual Property Portfolio
Expanding LNC Intellectual Property Portfolio 30 ISSUED U.S. & FOREIGN PATENTS EXTEND TO AT LEAST 2033 20 Patents Issued Within Last 5 Years 24 30+ PENDING PATENT APPLICATIONS ACROSS PLATFORM COULD EXTEND TO 2040 Additional IP to be developed as clinical development plan progresses. Regulatory Exclu
Slide 25: Executive Officers and Board of Directors
Executive Officers and Board of Directors EXECUTIVE OFFICERS Jerome D. Jabbour Co-Founder, Chief Executive Officer Thomas Hoover, MBA Chief Business Officer James J. Ferguson Ill, M.D., FACC, FAHA Chief Medical Officer Theresa Matkovits, Ph.D. Chief Development Officer Keith A. Kucinski, CPA, MBA Ch
Slide 26: Summary and 2022 Milestones & Catalysts
Summary and 2022 Milestones & Catalysts 1H 2022 Milestones & Catalysts 2H 2022 Milestones & Catalysts FDA Feedback on Cohort 5 of I Interim Topline Data from Cohort EnACT 4 of EnACT MAT2203 Initiate preclinical studies of | | Data from MAT2203 preclinical MAT2203 in C. auris and studies in C. auris
Slide 27: Matinas BioPharma Corporate Presentation May 2022
MATINA BIOPHARMA XN Corporate ena May 2022
Matinas BioPharma Holdings — Investor Presentation (May 2022) on 6ix